| Assessment Status | Rapid Review Complete |
| HTA ID | 25014 |
| Drug | Tislelizumab |
| Brand | Tevimbra® |
| Indication | Tislelizumab (Tevimbra®) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 18/02/2025 |
| Rapid review completed | 04/03/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tislelizumab compared with the current standard of care. |
The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.
Further information on the status of this application may be found here.